Full Prescribing Information and Instructions for Use
ENGLISH ESPAÑOL
For Patients and Caregivers
Kineret and IL-1 Patient Insights Kineret RA Data Kineret NOMID Data KINERET® On TRACK Resources

Resources for you and your patients

Kineret dose calculator

Calculate the volume of Kineret needed for a patient's weight and dose

WEIGHT

KG

DOSE STRENGTH


## mg

1 syringe = 100 mg. Doses greater than 100 mg will require more than one syringe

Downloadable patient materials

Kineret injection tracker

Printable sheets patients and caregivers can use to keeping track of injection sites.


Kineret treatment guide

A brochure with information about how Kineret works, how to store and inject Kineret, and details about the services of KINERET® On TRACK. Suitable for patients with RA or NOMID.


Kineret instructions for use

Instructions for storing and injecting Kineret.

INDICATION

Kineret® is an interleukin-1 receptor antagonist indicated for:

Rheumatoid Arthritis (RA)

  • Reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis, in patients 18 years of age or older who have failed 1 or more disease-modifying antirheumatic drugs (DMARDs)

Cryopyrin-Associated Periodic Syndromes (CAPS)

  • Treatment of Neonatal-Onset Multisystem Inflammatory Disease (NOMID)

IMPORTANT SAFETY INFORMATION

  • Kineret is contraindicated in patient with known hypersensitivity to E. coli-derived proteins, Kineret, or to any components of the product
  • In RA, discontinue use if serious infection develops. In Kineret-treated NOMID patients, the risk of a NOMID flare when discontinuing Kineret treatment should be weighed against the potential risk of continued treatment. Do not initiate Kineret in patients with active infections
  • Use in combination with Tumor Necrosis Factor (TNF) blocking agents is not recommended
  • Hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported
  • The impact of treatment with Kineret on active and/or chronic infections and the development of malignancies is not known
  • Live vaccines should not be given concurrently with Kineret
  • Neutrophil counts should be assessed prior to initiating Kineret treatment, and while receiving Kineret, monthly for 3 months, and thereafter quarterly for a period up to 1 year
  • RA: Most common adverse reactions (incidence ≥ 5%) are injection site reaction, worsening of rheumatoid arthritis, upper respiratory tract infection, headache, nausea, diarrhea, sinusitis, arthralgia, flu-like symptoms, and abdominal pain
  • NOMID: The most common AEs during the first 6 months of treatment (incidence > 10%) are injection site reaction, headache, vomiting, arthralgia, pyrexia, and nasopharyngitis
  • A higher rate of serious infections has been observed in RA patients treated with concurrent Kineret and etanercept therapy than in patients treated with etanercept alone. Use of Kineret in combination with TNF blocking agents is not recommended
  • Because there is a higher rate of infections in the elderly population in general, caution should be used in treating the elderly
  • Kineret is substantially excreted by the kidney, and the risk of toxic reactions to Kineret may be greater in patients with impaired renal function

Please see full Prescribing Information.